• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Home
  • LinkedIn
  • Twitter

  • About Us
    • Overview
    • Executive Committee
    • Board Of Directors
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • Our Technology
      • TIM
      • shRNA
      • shARC Platform
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
    • Media Center
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Careers
  • Contact Us

Celyad participating in Large and Midcap Event in Paris

September 2, 2015 By Celyad

Mont-Saint-Guibert, Belgium – Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, announces its participation in the 15th edition of the European Large & Midcap Event, which will be held in Paris this coming October 7th and 8th.

By participating in this event focusing especially on European midcap companies, Celyad is seizing the opportunity to share its strategy and present its main development programmes to European institutional investors and analysts.

Patrick Jeanmart, Administrative and Financial Director of Celyad, comments: “We are delighted to be participating once again in the Large and Midcap Event. For two years, Celyad has been developing firm ties with European institutional investors. This event is ideal for sharing with them the major advances our company has achieved in recent months in our cardiology and oncology programmes”.

Download press release(s)
Communiqué de presse
Press Release

Filed Under: Corporate, Non-regulated

Footer

Celyad Oncology

Celyad Oncology Logo
  • About
  • Science
  • Pipeline
  • Newsroom
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2020 All Rights Reserved.

  • Cookie Policy |
  • Privacy Policy |
  • Terms of Use